ACE2 and COVID-19: Initially, much of the scientific discussion regarding RAAS and COVID-19 treatment focused on angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB)7–9, and the hypothesis that ACEi and ARB might increase ACE2 expression and thus increase infection risk and severity10,11.